Imaging Biometrics Ltd (IBAI) has acquired an 86% controlling stake in Kirkstall, a developer of lab systems that mimic organ interaction for drug testing, in a £170,000 deal. The transaction, largely financed by issuing a convertible loan note to Truetide, Kirkstall's former majority owner and a significant shareholder in IBAI, is expected to complement Imaging Biometrics' existing work and strengthen its position in the advanced cell-based testing market. This strategic acquisition aims to accelerate Kirkstall's expansion, particularly into the growing US market, and was independently reviewed as a related-party transaction.
Imaging Biometrics Ltd (IBAI) has acquired an 86% controlling stake in Kirkstall, a developer of organ-mimicking lab systems, for £170,000. This strategic move aims to bolster IBAI's presence in the advanced cell-based testing market and leverage its network to accelerate Kirkstall's expansion, particularly into the growing US market. Kirkstall's Quasi Vivo system, already in use in the UK, offers a more realistic drug testing platform. The acquisition is largely financed by a £170,000 unsecured convertible loan note issued to Truetide, Kirkstall's former majority owner, bearing 6% annual interest and convertible into IBAI shares by 2027 at a dynamic price. A smaller cash outlay of under £24,000 covers other Kirkstall shareholders. This structure minimizes immediate cash drain for IBAI. Given Truetide's 29% stake in IBAI and a shared director, the transaction was classified as a related-party deal, though independent directors deemed it "fair and reasonable." The moderately positive sentiment and optimistic tone surrounding the announcement suggest market approval of the strategic rationale and potential synergies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately positive
Sentiment Score
0.60
